This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Successful research in targeted protein degradation depends not only on measurements at high sensitivity, speed and precision ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

The applied physicist explains how the structure of 52,000-year-old genes hint at the biology of an extinct animal ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling ...

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.

Total revenue of $59.3 million for the fiscal year ended December 31, 2024Expect double digit growth for total revenue in 20252025 to demonstrate ...